John M. Lachin - Concepedia

Author

John M. Lachin

Also Known As

A.A. Bremer, Barbara H Braffett, Barbara H. Braffet, C. Beck, D.M. Nathan, David M Nathan, Ellen Leschek, Grado, Carlos Raffo, Heidi Krause-Steinrauf, J LACHIN

510

Publications

56.1K

Citations

101

H-Index

201

Concepts

All Affiliations

George Washington University University of Washington University of Toronto University of Michigan Case Western Reserve University

About

John M. Lachin is an author at George Washington University specializing in medicine, diabetes, and statistics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	63	6.1K
2	Health Sciences	16	18	3.2K
3	Engineering	8	8	1.4K
4	Education	3	3	48
5	Arts	1	1	13

John M. Lachin

236

Publications

47.8K

Citations

H-Index

Page 1

	Year	Citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin, New England Journal of Medicine	2015	11.6K
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, New England Journal of Medicine	2016	3.5K
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Steven E. Kahn, Steven M. Haffner, Mark Heise, New England Journal of Medicine	2006	2.9K
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, New England Journal of Medicine	2015	2.5K
Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes Richard F. Hamman, Rena R. Wing, Sharon L. Edelstein, Diabetes Care	2006	1.3K
Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf, New England Journal of Medicine	2009	1.1K
Introduction to sample size determination and power analysis for clinical trials John M. Lachin Controlled Clinical Trials Power AnalysisEngineeringSize DeterminationClinical TrialsRandomized Controlled Trial	1981	1K
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial Silvio E. Inzucchi, Bernard Zinman, David Fitchett, Diabetes Care	2017	721
Statistical Considerations in the Intent-to-Treat Principle John M. Lachin Controlled Clinical Trials Statistical ThinkingBehavioral Decision MakingStatistical ConsiderationsField ExperimentQuasi-experiment	2000	651
Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program William H. Herman, Yong Ma, Gabriel I. Uwaifo, Diabetes Care	2007	569

Page 1